Verrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VRCA
Verrica Pharmaceuticals Inc. (VRCA) EV/Sales
As of 16 October 2026, Verrica Pharmaceuticals Inc. (VRCA) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 0.0× (September 2022) to 92.3× (December 2023); the current reading is higher than 57% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (56.10%) |
| FY2024 | 4.6× | (91.73%) |
| FY2023 | 55.3× | 661.22% |
| FY2022 | 7.3× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 54.43% |
| Mar 2026 | 2.8× | 40.79% |
| Dec 2025 | 2.0× | 13.62% |
| Sep 2025 | 1.8× | (64.25%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XBIT XBiotech Inc. compare | −8.6× |
| FBIO Fortress Biotech, Inc. compare | −1.4× |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 0.2× |
| CSBR Champions Oncology, Inc. compare | 1.0× |
| VRCA Verrica Pharmaceuticals Inc. | 2.6× |
| HYFT MindWalk Holdings Corp. compare | 5.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)